Even if the anti-CD38 daratumumab has been approved in multiple myeloma patients [35] and preclinically assessed against T-ALL [36], a careful clinical monitoring is required for on-target off-tumor toxicities in these frail patients. This evidence concerns the gene CD38 and plasma cell myeloma.